Dickran Kazandjian1,2, Yutao Gong1, Patricia Keegan1, Richard Pazdur1, Gideon M Blumenthal1. 1. Oncology Center of Excellence, Office of Hematology and Oncology Products, US Food and Drug Administration, Silver Spring, Maryland. 2. Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
IMPORTANCE: Previous studies have suggested the importance of the baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) level as prognostic markers. The lung immune prognostic index (LIPI) was shown to be associated with progression-free survival (PFS) and overall survival (OS) among patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs) but not cytotoxic chemotherapy (CCT). OBJECTIVE: To determine whether the LIPI is associated with long-term outcomes in pooled analyses of clinical studies of ICI and targeted therapy (TT) for patients with mNSCLC. DESIGN, SETTING, AND PARTICIPANTS: An exploratory pooled analysis was performed of the LIPI on data from 11 randomized clinical multinational trials evaluating ICIs and TT submitted to the US Food and Drug Administration between January 1, 2013, and December 31, 2017, for 4914 patients with mNSCLC. Lung immune prognostic index scores were calculated based on the dNLR and the LDH level per previous publications to generate good, intermediate, and poor composite scores. Multivariable Cox proportional PFS and OS hazard ratios were generated for the dNLR, the LDH level, age, smoking status, histologic characteristics, and Eastern Cooperative Oncology Group performance score. MAIN OUTCOMES AND MEASURES: Overall survival and PFS and their association with good, intermediate, or poor prognostic LIPI scores. RESULTS: Eleven mNSCLC randomized trials were analyzed, including 3987 patients with available data. In 5 ICI trials comprising 2440 patients, 1368 patients received ICIs and 1072 patients received CCT. In 6 TT trials comprising 1547 patients, 1110 patients received TT and 437 patients received CCT. A good LIPI score was associated with better OS among patients receiving ICIs (hazard ratio, 0.34; 95% CI, 0.28-0.42), TT (hazard ratio, 0.28; 95% CI, 0.21-0.37), and CCT (hazard ratio, 0.49; 95% CI, 0.40-0.60 in ICI trials; hazard ratio, 0.41; 95% CI, 0.27-0.61 in TT trials) than those with poor LIPI scores. Similar findings were observed in terms of PFS (ICIs: hazard ratio, 0.59; 95% CI, 0.48-0.72; TT: hazard ratio, 0.46; 95% CI, 0.37-0.57; and CCT: hazard ratio, 0.56; 95% CI, 0.45-0.68 in ICI trials; hazard ratio, 0.51; 95% CI, 0.38-0.69 in TT trials). CONCLUSIONS AND RELEVANCE: The baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC. As further prospective clinical trial information is collected, the role of the LIPI score can be better defined.
IMPORTANCE: Previous studies have suggested the importance of the baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) level as prognostic markers. The lung immune prognostic index (LIPI) was shown to be associated with progression-free survival (PFS) and overall survival (OS) among patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs) but not cytotoxic chemotherapy (CCT). OBJECTIVE: To determine whether the LIPI is associated with long-term outcomes in pooled analyses of clinical studies of ICI and targeted therapy (TT) for patients with mNSCLC. DESIGN, SETTING, AND PARTICIPANTS: An exploratory pooled analysis was performed of the LIPI on data from 11 randomized clinical multinational trials evaluating ICIs and TT submitted to the US Food and Drug Administration between January 1, 2013, and December 31, 2017, for 4914 patients with mNSCLC. Lung immune prognostic index scores were calculated based on the dNLR and the LDH level per previous publications to generate good, intermediate, and poor composite scores. Multivariable Cox proportional PFS and OS hazard ratios were generated for the dNLR, the LDH level, age, smoking status, histologic characteristics, and Eastern Cooperative Oncology Group performance score. MAIN OUTCOMES AND MEASURES: Overall survival and PFS and their association with good, intermediate, or poor prognostic LIPI scores. RESULTS: Eleven mNSCLC randomized trials were analyzed, including 3987 patients with available data. In 5 ICI trials comprising 2440 patients, 1368 patients received ICIs and 1072 patients received CCT. In 6 TT trials comprising 1547 patients, 1110 patients received TT and 437 patients received CCT. A good LIPI score was associated with better OS among patients receiving ICIs (hazard ratio, 0.34; 95% CI, 0.28-0.42), TT (hazard ratio, 0.28; 95% CI, 0.21-0.37), and CCT (hazard ratio, 0.49; 95% CI, 0.40-0.60 in ICI trials; hazard ratio, 0.41; 95% CI, 0.27-0.61 in TT trials) than those with poor LIPI scores. Similar findings were observed in terms of PFS (ICIs: hazard ratio, 0.59; 95% CI, 0.48-0.72; TT: hazard ratio, 0.46; 95% CI, 0.37-0.57; and CCT: hazard ratio, 0.56; 95% CI, 0.45-0.68 in ICI trials; hazard ratio, 0.51; 95% CI, 0.38-0.69 in TT trials). CONCLUSIONS AND RELEVANCE: The baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC. As further prospective clinical trial information is collected, the role of the LIPI score can be better defined.
Authors: Alex K Bryant; Kamya Sankar; Garth W Strohbehn; Lili Zhao; David Elliott; Angel Qin; Sarah Yentz; Nithya Ramnath; Michael D Green Journal: Lung Cancer Date: 2021-12-02 Impact factor: 5.705
Authors: Juan Ruiz-Bañobre; María C Areses-Manrique; Joaquín Mosquera-Martínez; Alexandra Cortegoso; Francisco J Afonso-Afonso; Noemí de Dios-Álvarez; Natalia Fernández-Núñez; Cristina Azpitarte-Raposeiras; Margarita Amenedo; Lucía Santomé; José Luis Fírvida-Pérez; Rosario García-Campelo; Jorge García-González; Joaquín Casal-Rubio; Sergio Vázquez Journal: Transl Lung Cancer Res Date: 2019-12
Authors: Daan P Hurkmans; Sebastiaan D T Sassen; Karlijn de Joode; Lisanne Putter; Edwin A Basak; Annemarie J M Wijkhuijs; Markus Joerger; Reno Debets; Birgit C P Koch; Cor H Van der Leest; Marco W J Schreurs; Astrid A M van der Veldt; Joachim G J V Aerts; Ron H J Mathijssen; Stijn L W Koolen Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751